MCID: VSC012
MIFTS: 42

Vesiculobullous Skin Disease

Categories: Skin diseases

Aliases & Classifications for Vesiculobullous Skin Disease

MalaCards integrated aliases for Vesiculobullous Skin Disease:

Name: Vesiculobullous Skin Disease 12 15 17
Skin Diseases, Vesiculobullous 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2731
MeSH 45 D012872
UMLS 74 C0037275

Summaries for Vesiculobullous Skin Disease

Disease Ontology : 12 A skin disease that is characterized by fluid filled blisters.

MalaCards based summary : Vesiculobullous Skin Disease, also known as skin diseases, vesiculobullous, is related to pemphigoid gestationis and epidermolysis bullosa, and has symptoms including pruritus and exanthema. An important gene associated with Vesiculobullous Skin Disease is COL7A1 (Collagen Type VII Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and Integrin Pathway. The drugs Dapsone and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are craniofacial and digestive/alimentary

Related Diseases for Vesiculobullous Skin Disease

Diseases related to Vesiculobullous Skin Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Related Disease Score Top Affiliating Genes
1 pemphigoid gestationis 31.9 COL17A1 DST
2 epidermolysis bullosa 29.0 COL17A1 COL7A1 DST ITGB4 KLHL24 KRT14
3 skin disease 27.6 COL17A1 COL7A1 DST ITGB4 KRT14 KRT5
4 epithelial basement membrane dystrophy 10.3 COL17A1 PLEC
5 epidermolysis bullosa with pyloric atresia 10.2 ITGB4 PLEC
6 epidermolysis bullosa simplex with pyloric atresia 10.2 ITGB4 PLEC
7 benign breast adenomyoepithelioma 10.2 KRT14 KRT5
8 breast adenomyoepithelioma 10.2 KRT14 KRT5
9 epidermolysis bullosa simplex, autosomal recessive 1 10.2 KRT14 KRT5
10 large cell acanthoma 10.2 KRT14 KRT5
11 apocrine sweat gland neoplasm 10.2 KRT14 KRT5
12 breast squamous cell carcinoma 10.2 KRT14 KRT5
13 epidermolysis bullosa simplex with mottled pigmentation 10.2 KRT14 KRT5
14 cervical clear cell adenocarcinoma 10.2 KRT14 KRT5
15 odontoma 10.2 KRT14 KRT5
16 breast myoepithelial neoplasm 10.2 KRT14 KRT5
17 breast benign neoplasm 10.2 KRT14 KRT5
18 thoracic benign neoplasm 10.2 KRT14 KRT5
19 lipoadenoma 10.2 KRT14 KRT5
20 maternal uniparental disomy of chromosome 1 10.2 LAMA3 LAMB3 LAMC2
21 epidermolysis bullosa simplex, dowling-meara type 10.2 KRT14 KRT5
22 lipid-rich carcinoma 10.2 KRT14 KRT5
23 epidermolysis bullosa, junctional, herlitz type 10.2 LAMA3 LAMB3 LAMC2
24 pregnancy adenoma 10.2 KRT14 KRT5
25 sweat gland disease 10.2 KRT14 KRT5
26 intraneural perineurioma 10.1 KRT14 KRT5
27 tonsil cancer 10.1 KRT14 KRT5
28 pre-malignant neoplasm 10.1 KRT14 KRT5
29 aplasia cutis congenita 10.1 COL7A1 ITGB4
30 oropharynx cancer 10.1 KRT14 KRT5
31 hard palate cancer 10.1 KRT14 KRT4
32 lichen planopilaris 10.1 COL17A1 KRT14 KRT5
33 spindle cell carcinoma 10.1 KRT14 KRT5
34 hymenolepiasis 10.1 KRT4 KRT5
35 cloacogenic carcinoma 10.0 KRT4 KRT5
36 epidermolysis bullosa dystrophica 10.0 COL7A1 DST
37 lichen disease 10.0 COL17A1 DST
38 white sponge nevus 1 10.0 KRT14 KRT4 PLEC
39 ecthyma 9.9 COL17A1 DST
40 epidermolysis bullosa simplex, localized 9.9 ITGB4 KRT14 KRT5
41 epidermolysis bullosa simplex, generalized 9.9 KLHL24 KRT14 KRT5
42 neurotic excoriation 9.9 COL17A1 COL7A1 DST
43 in situ carcinoma 9.9 ITGB4 KRT14 KRT5
44 primary cutaneous amyloidosis 9.9 KRT14 KRT5
45 bullous skin disease 9.9 COL17A1 DST LAMA3
46 epidermolysis bullosa simplex with muscular dystrophy 9.9 COL17A1 DST PLEC
47 pyloric atresia 9.9 COL17A1 ITGB4 LAMC2 PLEC
48 subcorneal pustular dermatosis 9.9 COL17A1 DST
49 cellulitis 9.9 COL17A1 DST LAMA3
50 paraneoplastic pemphigus 9.8 COL17A1 DST

Graphical network of the top 20 diseases related to Vesiculobullous Skin Disease:



Diseases related to Vesiculobullous Skin Disease

Symptoms & Phenotypes for Vesiculobullous Skin Disease

UMLS symptoms related to Vesiculobullous Skin Disease:


pruritus, exanthema

MGI Mouse Phenotypes related to Vesiculobullous Skin Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.92 COL7A1 ITGB4 KRT14 KRT4 KRT5 LAMA3
2 digestive/alimentary MP:0005381 9.86 COL7A1 ITGB4 KRT14 KRT4 KRT5 LAMA3
3 growth/size/body region MP:0005378 9.85 COL7A1 ITGB4 KRT14 KRT4 KRT5 LAMA3
4 integument MP:0010771 9.65 COL7A1 ITGB4 KRT14 KRT4 KRT5 LAMA3
5 mortality/aging MP:0010768 9.32 COL7A1 ITGB4 KRT14 KRT4 KRT5 LAMA3

Drugs & Therapeutics for Vesiculobullous Skin Disease

Drugs for Vesiculobullous Skin Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 247)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4,Phase 2,Phase 1 80-08-0 2955
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
3
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 53-03-2 5865
5
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 25122-46-7, 25122-41-2 5311051 32798
6
Omalizumab Approved, Investigational Phase 4 242138-07-4
7
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 22916-47-8 4189
10
Sargramostim Approved, Investigational Phase 4,Phase 2 123774-72-1, 83869-56-1
11
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
12
Ticagrelor Approved Phase 4 274693-27-5 9871419
13
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
14
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
16
Calcium Approved, Nutraceutical Phase 4,Phase 3 7440-70-2 271
17
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
19 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1
20 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
21 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
22 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Folate Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
29 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
35 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
40 Ophthalmic Solutions Phase 4
41 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
44 Respiratory System Agents Phase 4
45 Anti-Asthmatic Agents Phase 4
46 Anti-Allergic Agents Phase 4,Phase 3
47 Immunoglobulin E Phase 4
48 Betamethasone Valerate Phase 4 2152-44-5
49 Vasoconstrictor Agents Phase 4
50 Calcium, Dietary Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa Unknown status NCT00336154 Phase 4 tetracyclin
3 Evaluation of Three Types of Dressings After Hip Surgery Completed NCT01469871 Phase 4
4 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
5 The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients Completed NCT03848871 Phase 4 Enstilar
6 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
7 Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa Completed NCT00231517 Phase 4 topical opiod;morphine sulphate in intrasite gel
8 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
9 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Recruiting NCT02360202 Phase 4 Clobetasol Propionate cream treatment
10 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction Recruiting NCT02931045 Phase 4 Ticagrelor;Clopidogrel
11 G-CSF in the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
12 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Not yet recruiting NCT03926377 Phase 4
13 Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis Terminated NCT01115244 Phase 4 Dapsone gel, 5%
14 A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa Terminated NCT01619670 Phase 4
15 Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
16 Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus Unknown status NCT01974518 Phase 3 Rituximab and Cyclophosphamide IV
17 Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin Unknown status NCT01340235 Phase 3 Oral erythromycin
18 Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris Completed NCT02828163 Phase 3 Triamcinolone Acetonide
19 Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris Completed NCT01920477 Phase 3
20 Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Completed NCT01408550 Phase 3 NPB-01;Placebo
21 Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab Completed NCT01299857 Phase 3 Rituximab
22 Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus Completed NCT00784589 Phase 3 General Corticotherapy;Rituximab
23 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV) Completed NCT00683930 Phase 3 Mycophenolate Mofetil 2 g/Day;Mycophenolate Mofetil (MMF) 3 g/Day;Placebo
24 Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Completed NCT00525616 Phase 3 Mabthera
25 Effect of Anti CD20 in Pemphigus Desease Completed NCT00213512 Phase 2, Phase 3 Mabthera
26 European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus Completed NCT00127764 Phase 2, Phase 3 dexamethasone (50mg 1dd6, 3 consecutive days/month)
27 Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs Completed NCT01065116 Phase 3 AL Blister-packs with Instruction leaflets;AL unit dose age specific pre-packs
28 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Completed NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
29 ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa Completed NCT02384460 Phase 3 SD-101-6.0 cream;Placebo (SD-101-0.0) cream
30 Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer Completed NCT01825642 Phase 2, Phase 3
31 Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
32 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Completed NCT00346450 Phase 3
33 A Study of PRN1008 in Patients With Pemphigus Recruiting NCT03762265 Phase 3 PRN1008 Oral Tablet;Placebo Oral Tablet
34 Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex Recruiting NCT03453632 Phase 2, Phase 3 Botulinic toxin;Placebo
35 Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa Recruiting NCT03068780 Phase 3 Oleogel-S10;Placebo
36 A Comparative Study of the Healing of Chronic Ulcers of Recessive Epidermolysis Bullosa : Dressing vs Amniotic Membrane Recruiting NCT02286427 Phase 3
37 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Active, not recruiting NCT02383589 Phase 3 Mycophenolate Mofetil Placebo;Mycophenolate Mofetil;Rituximab;Rituximab Placebo
38 Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial Not yet recruiting NCT03790293 Phase 3 Rituximab;corticosteroids'therapy
39 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Not yet recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
40 Pregabalin Treatment for RDEB Pain and Itch Not yet recruiting NCT03928093 Phase 3 Pregabalin
41 Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
42 Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Terminated NCT02613910 Phase 3 Ofatumumab;Acetaminophen/paracetamol;Antihistamine (cetirizine or equivalent);Prednisone/Prednisolone
43 A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing Terminated NCT01749306 Phase 3
44 Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB) Terminated NCT00587223 Phase 3
45 Subconjunctival Bevacizumab Effect on Bleb Vascularity Unknown status NCT00854529 Phase 2 Bevacizumab
46 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Unknown status NCT00802243 Phase 2 leflunomide
47 Diacerin for the Treatment of Epidermolysis Bullosa Simplex Unknown status NCT02470689 Phase 2 Diacerin cream
48 Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa Unknown status NCT02579369 Phase 1, Phase 2
49 Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa Unknown status NCT02323789 Phase 1, Phase 2 Mesenchymal stromal cells
50 Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita Unknown status NCT00936533 Phase 2 Dysport® (Botulinumtoxin A (Btx A));Placebo

Search NIH Clinical Center for Vesiculobullous Skin Disease

Cochrane evidence based reviews: skin diseases, vesiculobullous

Genetic Tests for Vesiculobullous Skin Disease

Anatomical Context for Vesiculobullous Skin Disease

MalaCards organs/tissues related to Vesiculobullous Skin Disease:

42
Skin, Eye, T Cells, Salivary Gland, Testes, Endothelial, Tonsil

Publications for Vesiculobullous Skin Disease

Articles related to Vesiculobullous Skin Disease:

# Title Authors Year
1
Vesiculobullous skin disease with prominent immunologic feature. ( 3312674 )
1987

Variations for Vesiculobullous Skin Disease

Expression for Vesiculobullous Skin Disease

Search GEO for disease gene expression data for Vesiculobullous Skin Disease.

Pathways for Vesiculobullous Skin Disease

Pathways related to Vesiculobullous Skin Disease according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 COL17A1 COL7A1 ITGB4 LAMA3 LAMA4 LAMB3
2
Show member pathways
13.21 COL17A1 COL7A1 ITGB4 LAMA3 LAMA4 LAMB3
3
Show member pathways
12.89 COL17A1 COL7A1 ITGB4 LAMA3 LAMA4 LAMB3
4
Show member pathways
12.8 ITGB4 LAMA3 LAMA4 LAMB3 LAMC2
5
Show member pathways
12.72 ITGB4 LAMA3 LAMA4 LAMB3 LAMC2
6
Show member pathways
12.64 ITGB4 LAMA3 LAMA4 LAMB3 LAMC2
7 12.6 LAMA3 LAMA4 LAMB3 LAMC2
8
Show member pathways
12.33 ITGB4 LAMA3 LAMA4 LAMB3 LAMC2
9
Show member pathways
12.32 COL17A1 DST ITGB4 LAMA3 LAMB3 LAMC2
10
Show member pathways
12.28 COL17A1 COL7A1 DST ITGB4 LAMA3 LAMB3
11
Show member pathways
12.11 LAMA3 LAMA4 LAMB3 LAMC2
12
Show member pathways
12.02 COL17A1 COL7A1 ITGB4 LAMA3 LAMA4 LAMB3
13
Show member pathways
11.99 ITGB4 LAMA3 LAMA4 LAMB3 LAMC2
14
Show member pathways
11.93 COL17A1 COL7A1 DST ITGB4 LAMA3 LAMA4
15 11.79 LAMA3 LAMA4 LAMB3 LAMC2
16 11.76 LAMA3 LAMA4 LAMB3 LAMC2
17
Show member pathways
11.69 DST KRT14 KRT4 KRT5 PLEC
18 11.52 LAMA3 LAMA4 LAMB3 LAMC2
19 11.2 ITGB4 LAMA4
20 11.12 ITGB4 LAMA3
21 11.08 COL17A1 ITGB4
22 10.77 COL17A1 COL7A1 ITGB4 LAMA3 LAMA4 LAMB3

GO Terms for Vesiculobullous Skin Disease

Cellular components related to Vesiculobullous Skin Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.8 COL17A1 DST ITGB4 KLHL24 PLEC
2 collagen-containing extracellular matrix GO:0062023 9.65 COL17A1 COL7A1 LAMA3 LAMA4 LAMC2
3 intermediate filament GO:0005882 9.55 DST KRT14 KRT4 KRT5 PLEC
4 keratin filament GO:0045095 9.54 KRT14 KRT4 KRT5
5 laminin-5 complex GO:0005610 9.32 LAMA3 LAMB3
6 hemidesmosome GO:0030056 9.26 COL17A1 DST ITGB4 PLEC
7 basement membrane GO:0005604 9.17 COL17A1 COL7A1 DST LAMA3 LAMA4 LAMB3

Biological processes related to Vesiculobullous Skin Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.8 COL7A1 DST ITGB4 LAMA3 LAMA4 LAMB3
2 extracellular matrix organization GO:0030198 9.7 COL17A1 COL7A1 ITGB4 LAMA3 LAMA4 LAMB3
3 keratinization GO:0031424 9.69 KRT14 KRT4 KRT5
4 cytoskeleton organization GO:0007010 9.65 DST KRT4 KRT5
5 cornification GO:0070268 9.54 KRT14 KRT4 KRT5
6 regulation of cell adhesion GO:0030155 9.52 LAMA3 LAMA4
7 endodermal cell differentiation GO:0035987 9.5 COL7A1 LAMA3 LAMB3
8 epidermis development GO:0008544 9.5 COL17A1 COL7A1 KRT14 KRT5 LAMA3 LAMB3
9 brown fat cell differentiation GO:0050873 9.49 LAMA4 LAMB3
10 cell motility GO:0048870 9.46 DST ITGB4
11 intermediate filament cytoskeleton organization GO:0045104 9.43 DST PLEC
12 regulation of embryonic development GO:0045995 9.4 LAMA3 LAMA4
13 hemidesmosome assembly GO:0031581 9.28 COL17A1 DST ITGB4 KRT14 KRT5 LAMA3

Molecular functions related to Vesiculobullous Skin Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 9.33 KRT14 KRT5 PLEC
2 extracellular matrix structural constituent conferring tensile strength GO:0030020 9.26 COL17A1 COL7A1
3 extracellular matrix structural constituent GO:0005201 9.26 COL17A1 LAMA3 LAMA4 LAMC2
4 structural molecule activity GO:0005198 8.92 DST LAMA3 LAMB3 PLEC

Sources for Vesiculobullous Skin Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....